STOCK TITAN

AI / ML Innovations (AIMLF) Stock News, Jun-Oct 2022

AIMLF OTC

AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.

News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.

Rhea-AI Summary

AI/ML Innovations Inc. announced that the British Columbia Securities Commission granted a management cease trade order (MCTO) affecting its CEO and CFO due to delays in filing required financial statements for the year ended April 30, 2022. The Company expects to file all necessary documents by October 28, 2022. The interim financial statements for the period ended July 31, 2022, also remain incomplete due to these delays. The Company will continue to provide bi-weekly updates during this period and is addressing accounting issues related to a France-based investee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.09%
Tags
AI
-
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF, FWB:42FB) announced a management cease trade order (MCTO) from the British Columbia Securities Commission due to delays in filing annual financial statements for the fiscal year ended April 30, 2022. As a result, the company also missed the deadline for interim filings due September 29, 2022. The company aims to file the required documents by October 28, 2022, while continuing to issue bi-weekly default reports. Failure to comply may lead to a cease trade order on its securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
AI
-
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced that the British Columbia Securities Commission (BCSC) granted a management cease trade order (MCTO) on August 30, 2022. This order prohibits the CEO and CFO from trading the company's securities until the filing of required audited financial statements for the year ending April 30, 2022. The company aims to file these documents by October 28, 2022, and will issue bi-weekly updates while in default. The MCTO does not hinder other shareholders from trading their securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
AI
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced its failure to file required audited annual financial statements for the year ending April 30, 2022, by the August 28, 2022 deadline, resulting in a default under National Instrument 51-102. The British Columbia Securities Commission has issued a management cease trade order (MCTO) which restricts insider trading but does not affect general shareholder trading. The company is actively working to rectify this situation and plans to complete required filings by October 28, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.90%
Tags
AI
-
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has applied for a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission due to the inability to file audited financial statements by the deadline of August 28, 2022. The delays are attributed to the acquisition of Tech2Heal SAS and the need for additional financial documentation to comply with IFRS. The company expects to file the required documents by October 28, 2022. The MCTO, if granted, will restrict trading of shares by the CEO and CFO but will not affect general public trading.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.00%
Tags
AI
-
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced a second pilot study for its Alakin healthcare management platform, launching in Paris, France. This study targets Parkinson's disease, affecting 200,000 individuals in France. Alakin features a user-friendly clinical dashboard and a mobile app for patient interaction, available in five languages. The platform aims to enhance productivity in healthcare settings through customizable care pathways and is set to deploy in various regions, including North America. The trial will integrate digital biomarkers for monitoring patient progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
AI
Rhea-AI Summary

AI/ML Innovations Inc. announces the successful results of its Annual General Meeting held on July 27, 2022. A total of 5,412,712 common shares were voted, representing 15.5% of issued shares, achieving quorum. Key resolutions passed include the election of 4 Directors: Tim Daniels, Nick Watters, Randy Duguay, and Bruce Matichuk, the appointment of Baker Tilly Canada as auditors, and the approval of the Company's Stock Option Plan. For more details, shareholders can refer to the Company's profile on SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
AI
-
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announces the upcoming launch of Alakin, a comprehensive healthcare management platform developed by its subsidiary Tech2Heal. This SaaS solution, built on FHIR standards, aims to improve patient engagement and optimize workflows in healthcare settings. A pilot study will commence at a 30,000-patient facility in Paris, with full deployment planned for August 2022. Alakin will streamline patient care processes, potentially leading to significant time and cost savings for healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
AI
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.91%
Tags
AI
Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a finalist in the prestigious i-Nov Innovation Contest. This recognition highlights the innovative potential of its Qookka digital therapy for mental health disorders, with less than 10% of entries making the cut. The contest, backed by the Programme d'Investissements d'Avenir in France, offers up to €5M in co-financing for winners. Qookka utilizes advanced AI algorithms and digital biomarkers for enhanced patient support and monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.50%
Tags
AI

FAQ

What is the current stock price of AI / ML Innovations (AIMLF)?

AI / ML Innovations (AIMLF) last closed at $0.0312.

What is the market cap of AI / ML Innovations (AIMLF)?

The market cap of AI / ML Innovations (AIMLF) is approximately $9.3M.